loader
Please Wait
Applying Filters...

Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    List of All Manufacturers & Suppliers for 204623 Licensing, EU CTD Dossiers, Marketing Authorizations, Finished Dosage Formulations listed on PharmaCompass.com

    Client Virtual Booth
    Menu

    Horizon Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Send me more info on How To Grow My Business Digitally?

    Left Arrow
    Right Arrow
    Filters Filter
    Cross PopUp
    FILTER :

    filter

    01 DICLOFENAC SODIUM (1)

    filter

    01 HORIZON (1)

    filter

    01 SOLUTION;TOPICAL (1)

    filter

    01 2% (1)

    filter

    01 USA (1)

    ListList of Suppliers
    refresh Reset Filter
    refresh Reset Filter
    product-page Supplier Virtual Booth
    price-trend Ask Us
    Contact Supplier
    • FDA
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
    Post an Enquiry Post an Enquiry
    Flag Ireland
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Diclofenac Sodium

    PDF Supplier PDF
    URL Supplier Web Content
    SOLUTION;TOPICAL
    2%
    PENNSAID
    USA
    204623
    2014-01-16
    RX
    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content

    Looking for CTD TGA MCC DOSSIER APPLICATION 204623

    Looking for CTD TGA MCC DOSSIER APPLICATION 204623 1

    19

    Horizon Therapeutics, based in Ireland, is a pharmaceutical company that stands out with its certifications from FDA.

    One of their notable products is DICLOFENAC SODIUM, with a corresponding application number 204623 and regulatory information .

    proudly manufactured in the

    approval since 2014-01-16

    Horizon Therapeutics's PENNSAID SOLUTION;TOPICAL, medication with 2% of DICLOFENAC SODIUM.

    Post Enquiry
    POST ENQUIRY